Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)

Obesity/Overweight Clinical Trial

Official title:
Pharmacological and Behavioral Treatments to Treat Loss-of-Control Eating and Improve Weight Outcomes After Bariatric Surgery: Maintenance Treatment (Stage 2a)

Status Enrolling by invitation

Clinical Trial Summary

This study will test the effectiveness of naltrexone/bupropion medication as a maintenance therapy for the treatment of loss-of-control eating and weight loss following bariatric surgery. This is a controlled test of whether, amongst responders to acute treatments, naltrexone/bupropion medication results in superior maintenance and longer-term outcomes compared with placebo.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04605081
Study type	Interventional
Source	Yale University
Contact
Status	Enrolling by invitation
Phase	Phase 2/Phase 3
Start date	January 10, 2022
Completion date	May 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05295875` - Efficacy and Safety of ALT-801 in the Treatment of Obesity	Phase 2
Recruiting	`NCT04599478` - Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)	Phase 2/Phase 3
Enrolling by invitation	`NCT04599504` - Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)	Phase 2/Phase 3